ArriVent Doses First U.S. Patient in ARR-002 Phase 1 Trial
ArriVent dosed the first U.S. patient in a Phase 1 study of ARR-002, a dual-target ADC for ovarian and endometrial cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
ArriVent doses first patient in Phase 1 trial of ARR — 002 dual — target ADC for ovarian, endometrial cancer
ArriVent dosed the first patient in a US Phase 1 trial of ARR-002 for ovarian and endometrial cancer. No clinical results have been presented yet; the update marks the study’s start rather than an efficacy or safety readout. ARR-002 is designed to target two tumor markers to improve drug delivery across tumors with mix